The stock of Juno Therapeutics Inc (NASDAQ:JUNO) is a huge mover today! About 2.73M shares traded hands or 28.17% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 50.36% since April 27, 2016 and is downtrending. It has underperformed by 55.59% the S&P500.
The move comes after 6 months negative chart setup for the $2.03B company. It was reported on Nov, 30 by Barchart.com. We have $18.75 PT which if reached, will make NASDAQ:JUNO worth $162.40M less.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 11 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. Juno Therapeutics Inc has been the topic of 23 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Northland Capital given on Wednesday, July 22. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. FBR Capital initiated the shares of JUNO in a report on Tuesday, August 18 with “Outperform” rating. Standpoint Research initiated it with “Buy” rating and $47.0 target price in Monday, August 24 report. On Thursday, October 29 the stock rating was downgraded by Standpoint Research to “Hold”. The stock has “Mkt Perform” rating given by FBR Capital on Wednesday, November 23. The company was upgraded on Tuesday, December 15 by Standpoint Research. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, August 5 with “Buy” rating. On Monday, November 28 the stock rating was maintained by Leerink Swann with “Outperform”. The rating was initiated by Raymond James on Thursday, June 2 with “Outperform”.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio is positive, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Aqr Cap Mgmt holds 0.02% or 232,432 shares in its portfolio. Checchi Capital Advisers Limited Liability Company has 162 shares for 0% of their US portfolio. Jane Street Gp Ltd Liability Com last reported 0% of its portfolio in the stock. Voya Invest Mngmt Ltd Llc owns 26,556 shares or 0% of their US portfolio. Deutsche National Bank Ag last reported 360,489 shares in the company. The Missouri-based Benjamin F Edwards Inc has invested 0.02% in Juno Therapeutics Inc (NASDAQ:JUNO). Winfield Assocs holds 20 shares or 0% of its portfolio. Point72 Asia (Hong Kong) has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). First Allied Advisory Service Inc, a Missouri-based fund reported 21,152 shares. 1832 Asset Mngmt Ltd Partnership last reported 0.01% of its portfolio in the stock. Ibm Retirement Fund has 0.01% invested in the company for 6,342 shares. Rhumbline Advisers has 55,351 shares for 0.01% of their US portfolio. Pub Employees Retirement Association Of Colorado accumulated 10,824 shares or 0% of the stock. Pictet Asset Mgmt has 180,438 shares for 0.03% of their US portfolio. The New York-based Citigroup has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO).
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016. Also Fool.com published the news titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. Marketwatch.com‘s news article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” with publication date: November 23, 2016 was also an interesting one.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.